Advertisement

Advertisement

Most Read Stories
Follow-up of Adjuvant Paclitaxel and Trastuzumab in Small HER2-Positive Breast Tumors
'Oral Cryotherapy' for Patients Undergoing Oxaliplatin-Based Chemotherapy
Lenvatinib in Recurrent or Metastatic Adenoid Cystic Carcinoma
KEYNOTE-158: Pembrolizumab in Previously Treated Advanced Cervical Cancer
Niraparib in Late-Line Treatment of Ovarian Cancer
Fallopian Tube Removal May Protect Premenopausal Women at High Risk for Ovarian Cancer From Some Surgical Side Effects
When Can Patients With Gleason 6 Prostate Cancer Safely Undergo Active Surveillance?
Complementary and Alternative Medicine Use in Patients With Cancer
Primary Surgery Outcomes in MRI-Based ‘Good-Prognosis’ Rectal Cancer
ASCO and ASH Release Update to Clinical Practice Guidelines for Use of Erythropoiesis-Stimulating Agents
Addition of Radiotherapy After Breast-Conserving Surgery Based on Level of Tumor-Infiltrating Lymphocytes
Treatment of Patients With Imminently Fatal de Novo Metastatic Cancer
FDA Pipeline: Designations for Myelodysplastic Syndromes, Triple-Negative Breast Cancer, AML, and EBV-Associated Cancers
Actionable Pathogenic Variants in a Population-Based Cohort of Patients With Breast or Ovarian Cancer
How I Work up the Patient with Thrombocytosis
Five-Fraction SBRT for Centrally Located, Inoperable NSCLC
Addition of Bortezomib to R-CHOP in DLBCL Subtypes Identified With Gene-Expression Profiling
Report Examines Shortages of Oncologists, Variation in Cancer Rates
FDA Approves Pembrolizumab Plus Axitinib for First-Line Treatment of Advanced Renal Cell Carcinoma
Fine-Tuning an ‘Airport Diagnosis’

Advertisement

Advertisement



;
Advertisement